undamentalytics Newsletter
Sign in

TG Therapeutics, Inc. cash flow statement

In fiscal 2025, TG Therapeutics, Inc.'s operations generated −$24.8m of cash; it spent $214,000 on capital projects, leaving free cash flow of −$25.0m. It returned $91.2m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−62−94−129−133−215−296−176−31−41−2518
Depreciation and amortisation00000000000
Stock-based pay816131180614538436581
Capital spending00000000000
Free cash flow−62−94−129−133−215−296−176−31−41−2517
Free cash flow after stock pay−69−110−142−144−295−357−221−69−83−90−64
Share buybacks——————00991178
Shares issued—————204600—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: TGTX vs TLXASND vs TGTXIONS vs TGTXRARE vs TGTX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from TG Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to TG Therapeutics, Inc.